Landmark approval advances personalized cancer care! Events, Seminars, & Publications 17. 01. 2019 The immense progress in molecular biology has contributed in the development of new anticancer drugs, which target specific cellular targets and molecules. This has led to an important progress in cancer therapies, at this point mainly for breast cancers, large intestinal cancers, lung cancers, melanomas, multiple myelomas, leukemias and other neoplastic diseases. The genetic profile test specifically for each cancer type has resulted to the administration of targeted therapy for each specific disease. The historical decision from the US Food and Drug administration – FDA and CMS – Centers for Medicaid Services to approve an innovative test for genomic profile testing of each cancer type, for each individual patient, represents a major advancement in personalized cancer care. The use of this test will transform anticancer therapy. This specific genomic profiling test can analyze hundreds of genes, which are related with each cancer type of the individual patient, in one analysis. It can be the solution from the test of the cancer cells to the recommended or suggested treatment solutions with the appropriate targeted medications or immunotherapies. The test allows the doctor to plan the personalized therapeutic scheme specific for each tumor type of each patient, providing the best care, with the highest benefit and less possible drug-related toxicity. How it works The doctor sends the tumor specimen to the lab for the isolation of DNA. The personal genomic profile of the tumor is identified. A group of genetic specialists analyze the data and correlates each tumor genomic profile with the available targeted medications or clinical trials. Sources: FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics http://investors.foundationmedicine.com/news-releases/news-release-details/fda-approves-foundation-medicines-foundationone-cdxtm-first-and Roche announces global availability of blood-based genomic profiling test, FoundationOne Liquid https://www.roche.com/media/releases/med-cor-2018-09-24.htm Tags: breast cancer , colon cancer , lung cancer , melanoma , leukemia
How likely are you to develop osteonecrosis of the jaw? Quality of Life 27. 06. 2025 Antiresorptive drugs help with osteoporosis and reduce bone complications in cancer patients, but they may cause osteonecrosis of the jaw (ONJ).Are you in the high-risk group?...[Read more]
Strength Through Community – Join Today! Quality of Life 11. 07. 2025 Two Communities, One Purpose: Support, Sharing, and Empowerment in Facing CancerCancer is not just a medical challenge. It is a deeply human experience that affects both patients and healthcare profes...[Read more]
Progress comes at a swift pace! Events, Seminars, & Publications 30. 11. 2024 MDcCON 2024. The conference took place on November 1 and 2 with outstanding success.The innate love for humanity and devotion to Medical Science are the oncologist’s tools in everyday life. Faith, hop...[Read more]